




OBIS Platform Portfolio

72 Products

2027-2034

72

PRODUCTS

2027-2034 HORIZON

- ⌋ Six-Generation Platform Architecture, Development
- ⌋ Waves and Partnership Optionality




OBIS Innovation & Solutions Inc.

OBIS Financial & Strategic Investment Series – 2027

PUBLIC INVESTOR MATERIAL

Executive Portfolio Positioning

The 2027–2034 portfolio framework presents breadth as strategic optionality, diversification and a source of future program creation and partnering.



2027 PORTFOLIO DEFINITION

OBIS presents a current platform architecture of 72 proposed products organized across six generations through the 2027–2034 planning horizon. The portfolio is not presented as 72 approved or clinical-stage assets; it is a structured opportunity set to be prioritized, protected and de-risked over time.

Core portfolio logic

- **Flagship anchoring.** LPS™ and SPI™ provide focused reference programs while the wider portfolio supports a broader platform thesis.
- **Diversification.** Multiple candidate families reduce strategic dependence on a single development outcome.
- **Staged development.** The portfolio is sequenced by evidence, IP, developability, market need and capital efficiency rather than advanced simultaneously.
- **Partnering optionality.** Candidates may support indication-specific, territory-specific or platform-level collaboration pathways.
- **Protected disclosure.** Investor-facing materials describe portfolio logic without disclosing enabling composition or replicable formulation details.

Portfolio metric	2027–2034 framing
Candidate universe	72 proposed products
Primary commercial platform	OBIS Biotech™
Flagship reference programs	LPS™ and SPI™
Portfolio horizon	2027–2034


Portfolio Domain Architecture

The 72-product platform spans multiple opportunity domains while preserving a single portfolio-management discipline and the six-generation financial architecture.

OBIS Platform Architecture - 72 Products

Portfolio domains are transverse strategic clusters within a six-generation product architecture.

Portfolio domains are strategic clusters; this document does not disclose formulation-level composition.



Current opportunity domains

- **Respiratory & immunoprotection.** Flagship and adjacent programs form the near-term scientific and commercial anchor.
- **Cross-sector expansion.** Current strategic materials identify oncology, neurology, dentistry, veterinary medicine, antimicrobial systems and device/delivery opportunities as part of the wider biotechnology platform.
- **No fixed domain allocation.** This investor document does not assign a public candidate count to each domain; program composition remains subject to portfolio review and IP strategy.

PORTFOLIO INTERPRETATION

“72 proposed products across six generations” is the current platform-level description. Portfolio breadth creates options, but value is expected to concentrate in a smaller set of programs that achieve evidence, IP and partner-readiness milestones. The opportunity domains shown here are transverse strategic clusters and do not replace the six-generation financial architecture.

Product Prioritization & Portfolio Governance

Portfolio discipline converts a broad product architecture into a capital-efficient development sequence.

Candidate Prioritization Framework

Candidates advance by evidence and strategic fit—not by portfolio count alone.



2027 prioritization principles

- **Scientific rationale.** Each program requires a coherent, testable biological thesis before material development spend.
- **IP defensibility.** Protection strategy, differentiation and freedom-to-operate review shape program priority.
- **Developability.** Delivery, manufacturing feasibility, quality and regulatory path must support advancement.
- **Market and system relevance.** Unmet need, market scale and potential health-economic value inform ranking but do not substitute for evidence.
- **Partnerability and capital efficiency.** External collaboration potential and milestone value relative to capital required are explicit portfolio filters.

GOVERNANCE RULE

The 72-product architecture is not a mandate to fund all programs. Portfolio management is expected to stop, defer, combine or partner programs as new evidence changes relative priority.

2027–2030: Definition, De-Risking & Proof-of-Concept Gate

The first phase of the portfolio horizon is designed to transform breadth into a smaller set of evidence-backed priority programs.



Period	Portfolio stage	Illustrative portfolio objective
2027	Define & protect	Confirm the 72-product / six-generation portfolio register; establish priorities; align IP, evidence plans, financing and external research pathways.
2028–2029	De-risk priority programs	Generate reproducible proof-of-concept packages, developability data and program-specific go/no-go criteria.
2030	Primary evidence gate	Advance only programs with sufficient evidence, IP position, feasibility and partner/commercial relevance.

Portfolio decision logic

- **Concentration before expansion.** Near-term capital is concentrated on the highest-priority programs rather than dispersed across the full candidate universe.
- **Evidence creates hierarchy.** Reproducible results, not original ranking, determine which candidates receive additional capital.
- **2030 as a portfolio gate.** The 2030 horizon represents an illustrative major inflection point for program continuation, partnering, licensing readiness or deprioritization.

INVESTOR READING

The first phase is not designed to maximize the number of active programs. It is designed to increase portfolio quality by reducing uncertainty around the products and programs with the strongest evidence and strategic fit.

2031–2034: Expansion, Partnering & Platform Scale

Later portfolio expansion depends on earlier evidence and on the capacity to finance or partner

2027–2034 Strategic Portfolio Sequencing

Illustrative sequencing framework; program-specific timelines remain evidence- and regulation-dependent.



Expansion framework

- **2031–2032 – selective expansion.** Validated flagship and adjacent programs can support broader domain expansion, co-development and territory- or indication-specific transactions.
- **2033–2034 – multi-program architecture.** The platform may support a wider network of partner-led development, licensing and international collaboration across selected domains.
- **Program-specific timing.** The portfolio horizon does not imply that every product or program reaches the same stage by 2034; each retains its own scientific and regulatory clock.
- **2034 review horizon.** The end of the current planning window is a portfolio-reprioritization point, not a terminal date for the platform.

Portfolio Partnership & Monetization Optionality

OBIS can pursue multiple transaction structures as programs mature, while preserving program-specific economics and avoiding double counting.



Portfolio Partnership & Monetization Pathways

Multiple routes may coexist, subject to program maturity and transaction-specific terms.

Indication-specific licensing

Territory-based licensing

Co-development

Sponsored research

Technology transfer

Milestone payments

Royalties

Strategic investment

Transaction principles

- **Program-level flexibility.** Licensing and co-development may be structured by indication, territory, candidate family or platform boundary.
- **Milestone-based economics.** Early research or option agreements can evolve into milestone payments, royalties or broader strategic participation as risk is reduced.
- **Institutional validation.** Sponsored research, scientific collaboration and external reproducibility can increase partner confidence before major commercial commitments.
- **No automatic portfolio transfer.** A transaction involving one program should not imply rights to unrelated candidates unless explicitly negotiated.

COMMERCIAL DISCIPLINE

Portfolio optionality should be monetized selectively. The objective is to preserve long-term platform value while using transactions to finance de-risking, expand capabilities and accelerate priority programs.

Portfolio Value-Creation Stack

Portfolio breadth has investment relevance only when it is converted into protected, validated and partnerable programs.

Portfolio Value-Creation Stack



What changes value perception

Value driver	Investor significance
IP protection	Converts scientific concepts into defined proprietary positions.
Reproducible proof-of-concept	Reduces scientific uncertainty and supports continuation decisions.
Developability & regulatory clarity	Improves visibility on execution, cost and pathway.
External validation	Adds scientific and institutional credibility.
Partner interest / transactions	Provides market confirmation and potential non-dilutive or strategic capital.
Manufacturing / delivery readiness	Supports scale and commercial feasibility.

VALUATION DISCIPLINE

The portfolio should not be valued by multiplying the 72-product count by a uniform per-asset value. The current formula-driven Pre-Money standard applies explicit cash-flow, timing, risk-realization, IP, maturity and anti-double-counting rules; product count is not a valuation multiplier.

Disclosure Governance & Portfolio Boundaries

The portfolio document communicates breadth and strategic optionality without exposing enabling technical information or blurring investment perimeters.



Disclosure rules

- **No formula-level disclosure.** The document does not disclose enabling composition, ingredient-level formula, proportions or other replicable technical details of protected programs.
- **No clinical-stage implication.** “72 proposed products” describes the current platform architecture; it should not be read as 72 approved products, IND-ready programs or clinical-stage assets.
- **No double counting.** LPS™, SPI™ and other flagship economics should not be added again at portfolio level when already embedded in a consolidated model.
- **Commercial perimeter.** OBIS Biotech™ is the principal commercial biotechnology platform for this portfolio document. Other OBIS divisions remain separately governed unless a specific investment perimeter is approved.
- **Controlled source.** The approved 2027 portfolio register should become the single source for candidate count, priority status, program stage and transaction status.

INVESTOR-FACING STANDARD

The 2027–2034 portfolio series presents opportunity, sequencing and value inflection. Detailed candidate composition, technical specifications and enabling formulation information remain subject to controlled disclosure and program-specific review.

Executive Portfolio Investment Case – 2027–2034

A concise synthesis of why a 72-product, six-generation platform may matter to investors without assuming that every product or program succeeds.



INVESTMENT CASE

OBIS presents a biotechnology platform in which flagship programs provide focus while 72 proposed products organized across six generations create additional scientific, strategic and transaction optionality. The portfolio thesis depends on disciplined prioritization: a smaller number of programs should absorb most near-term capital, and broader expansion should follow reproducible evidence, IP protection, developability, regulatory clarity and partner validation.

The 2027–2034 standard

- **Breadth with discipline.** Portfolio size provides optionality; selective advancement preserves capital efficiency.
- **Flagship-to-platform architecture.** Early value creation can improve confidence in adjacent candidates and future partnering without assuming automatic transfer of success.
- **Multi-domain reach.** Respiratory, immunoprotection, oncology, neurology, dentistry, veterinary, antimicrobial and device/delivery opportunities create multiple development and partnership pathways.
- **Milestone-based value.** IP, PoC, external validation, regulatory readiness and transactions are the primary drivers of portfolio value inflection.
- **2034 horizon.** The current planning window culminates in portfolio reprioritization and a more mature partnering architecture, followed by the next strategic horizon.

OBIS Innovation & Solutions Inc.

One Vision. Three Paradigms. A Shared Future.

OBIS Platform Portfolio – 72 Products – 2027–2034